Clinical studies on bacampicillin in the treatment of respiratory tract infections

Akira Watanabe; Kotaro Oizumi; Kiyoshi Konno; Izumi Hayashi

doi:10.11250/chemotherapy1953.27.907

Clinical studies on bacampicillin in the treatment of respiratory tract infections

Akira Watanabe, Kotaro Oizumi, Kiyoshi Konno, Izumi Hayashi

Research output: Contribution to journal › Article › peer-review

Abstract

Clinical investigations were performed on bacampicillin, a new orally well-absorbed semisynthetic penicillin which is high active in vivo due to rapid transformation into ampicillin. Bacampicillin was administered to total 27 cases of respiratory tract infections, at daily dose of 1.0 g for 28 days to 8 cases of bronchitis, 18 cases of pneumonia and a daily dose of 1.5 g for 14 days to a case of pneumonia. Clinical response of bacampicillin was excellent in 15 cases, good in 8 cases and fairly effective in 4 cases. Side effects with bacampicillin were observed in 3 cases consisting of one skin eruption, one eosinophilia and one elevation of serum transaminase. These turned to normal by discontinuing the drug.

Original language	English
Pages (from-to)	907-912
Number of pages	6
Journal	Chemotherapy
Volume	27
Issue number	6
DOIs	https://doi.org/10.11250/chemotherapy1953.27.907
Publication status	Published - 1979 Jan 1

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.27.907

Cite this

@article{4d7de36e202343bb9cdaf1b3225b74a8,

title = "Clinical studies on bacampicillin in the treatment of respiratory tract infections",

abstract = "Clinical investigations were performed on bacampicillin, a new orally well-absorbed semisynthetic penicillin which is high active in vivo due to rapid transformation into ampicillin. Bacampicillin was administered to total 27 cases of respiratory tract infections, at daily dose of 1.0 g for 28 days to 8 cases of bronchitis, 18 cases of pneumonia and a daily dose of 1.5 g for 14 days to a case of pneumonia. Clinical response of bacampicillin was excellent in 15 cases, good in 8 cases and fairly effective in 4 cases. Side effects with bacampicillin were observed in 3 cases consisting of one skin eruption, one eosinophilia and one elevation of serum transaminase. These turned to normal by discontinuing the drug.",

author = "Akira Watanabe and Kotaro Oizumi and Kiyoshi Konno and Izumi Hayashi",

year = "1979",

month = jan,

day = "1",

doi = "10.11250/chemotherapy1953.27.907",

language = "English",

volume = "27",

pages = "907--912",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

number = "6",

}

TY - JOUR

T1 - Clinical studies on bacampicillin in the treatment of respiratory tract infections

AU - Watanabe, Akira

AU - Oizumi, Kotaro

AU - Konno, Kiyoshi

AU - Hayashi, Izumi

PY - 1979/1/1

Y1 - 1979/1/1

N2 - Clinical investigations were performed on bacampicillin, a new orally well-absorbed semisynthetic penicillin which is high active in vivo due to rapid transformation into ampicillin. Bacampicillin was administered to total 27 cases of respiratory tract infections, at daily dose of 1.0 g for 28 days to 8 cases of bronchitis, 18 cases of pneumonia and a daily dose of 1.5 g for 14 days to a case of pneumonia. Clinical response of bacampicillin was excellent in 15 cases, good in 8 cases and fairly effective in 4 cases. Side effects with bacampicillin were observed in 3 cases consisting of one skin eruption, one eosinophilia and one elevation of serum transaminase. These turned to normal by discontinuing the drug.

AB - Clinical investigations were performed on bacampicillin, a new orally well-absorbed semisynthetic penicillin which is high active in vivo due to rapid transformation into ampicillin. Bacampicillin was administered to total 27 cases of respiratory tract infections, at daily dose of 1.0 g for 28 days to 8 cases of bronchitis, 18 cases of pneumonia and a daily dose of 1.5 g for 14 days to a case of pneumonia. Clinical response of bacampicillin was excellent in 15 cases, good in 8 cases and fairly effective in 4 cases. Side effects with bacampicillin were observed in 3 cases consisting of one skin eruption, one eosinophilia and one elevation of serum transaminase. These turned to normal by discontinuing the drug.

UR - http://www.scopus.com/inward/record.url?scp=85024311704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024311704&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.27.907

DO - 10.11250/chemotherapy1953.27.907

M3 - Article

AN - SCOPUS:85024311704

VL - 27

SP - 907

EP - 912

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

SN - 0009-3165

IS - 6

ER -

Clinical studies on bacampicillin in the treatment of respiratory tract infections

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this